The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...

The bosses of some of the world's biggest companies met with Chinese President Xi Jinping in Beijing on Friday.

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...